adjuvant
No description yet: the sentence for this tag has not been written. 7 records carry it: 7 people.
Related tags
7 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Dean F. Bajorin Attending Physician, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center Led CheckMate 274, which established adjuvant nivolumab after bladder cancer surgery. | Bladder & urothelial cancer | none | urothelial, immunotherapy | ||
Jason J. Luke Director, Cancer Immunotherapeutics Center, UPMC Hillman Cancer Center · UPMC Hillman Cancer Center Led KEYNOTE-716, which extended adjuvant pembrolizumab to high-risk stage II melanoma. | Melanoma | none | melanoma, early-phase | ||
Jeffrey S. Weber Deputy Director, NYU Langone Perlmutter Cancer Center; Professor of Medicine · Laura and Isaac Perlmutter Cancer Center at NYU Langone Health Led CheckMate 238, which made adjuvant nivolumab standard after melanoma surgery, and co-led the mRNA vaccine trial KEYNOTE-942. | Melanoma | none | melanoma, vaccine | ||
John M. Kirkwood Melanoma medical oncologist, UPMC Hillman Cancer Center · UPMC Hillman Cancer Center Pittsburgh melanoma doctor who ran the interferon trials that were the first adjuvant treatment for high-risk melanoma, and later led CheckMate 76K on adjuvant nivolumab for stage II disease. | Stage IIB and IIC melanoma, Stage III melanoma, Melanoma | none | melanoma, trialist | ||
Ronan J. Kelly Director, Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas · Charles A. Sammons Cancer Center, Baylor University Medical Center Led CheckMate 577, the first trial to show adjuvant immunotherapy helps oesophageal cancer patients with residual disease. | Oesophageal cancer, Gastric & gastro-oesophageal junction cancer | none | esophageal, immunotherapy | ||
Roy S. Herbst Deputy Director and Chief of Medical Oncology, Yale Cancer Center · Yale Cancer Center / Smilow Cancer Hospital Lung cancer trialist behind KEYNOTE-010 and the ADAURA adjuvant osimertinib trial. | Non-small-cell lung cancer | none | lung, immunotherapy | ||
Thierry André Professor of Medical Oncology, Sorbonne University; Head of Medical Oncology, Hôpital Saint-Antoine, Paris · Institut Universitaire de Cancérologie AP-HP Sorbonne Université Led MOSAIC, which made FOLFOX the adjuvant standard, and KEYNOTE-177, which made pembrolizumab first-line for MSI-high colon cancer. | Colorectal cancer | none | colorectal, immunotherapy |